CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Compass Pathways PLC (CMPS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as hedge fund interest and optimistic analyst ratings, the technical indicators, financial performance, and lack of recent news or significant trading signals suggest that the stock does not currently present a compelling entry point. Holding off for better clarity or improved signals is advisable.
The technical indicators show a bearish trend. The MACD is negatively expanding, RSI is neutral at 31.065, and moving averages are converging. The stock is trading near its support level (S1: 5.823), with no clear upward momentum.
Hedge funds are significantly increasing their positions, with a 302.54% increase in buying over the last quarter.
Analysts have raised price targets and maintain Outperform ratings, citing optimism about the company's COMP360 therapy and its potential market impact.
The stock has a 70% chance of modest gains (0.92%) in the next month based on historical patterns.
The stock experienced a significant regular market decline of -7.29%, indicating weak short-term sentiment.
Financial performance remains poor, with no revenue growth and a significant net loss in Q3
No recent news or congress trading data to act as a catalyst.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of -$137.7M (up 257.69% YoY), and an EPS of -1.44 (up 157.14% YoY). While losses have narrowed, the company remains unprofitable with no immediate signs of revenue generation.
Analysts are optimistic about the stock. RBC Capital raised the price target to $21 from $16, citing barriers to generic entry and the potential of psychedelic therapies. Oppenheimer upgraded the stock to Outperform with a $15 price target, highlighting the potential of COMP360 as a revolutionary treatment for depression.
